Cetylammonium | 21576-60-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Cetylammonium
• 英文别名: n-Hexadecylammonium；n-Hexadecanylammonium；Hexadecylammonium；Hexadecan-1-amine;hydron；hexadecan-1-amine;hydron
• CAS: 21576-60-3
• 化学式: C₁₆H₃₆N
• 分子量: 242.469
• InChiKey: FJLUATLTXUNBOT-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  17
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.6
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  9-氯吖啶 、 Cetylammonium 以80%的产率得到
  参考文献：
  名称：

  DNA strongly binds to micelles and vesicles containing lipopolyamines or lipointercalants.

  摘要：

  DOI：

  10.1016/s0040-4039(00)85347-2

文献信息

• Pharmaceutical compositions containing hyaluronic acid for use in the treatment of black disc disease
  申请人：FIDIA FARMACEUTICI S.P.A.

  公开号：US10064887B2

  公开（公告）日：2018-09-04

  The present invention describes and claims pharmaceutical compositions in gel form for use in the treatment of intervertebral disc degeneration, in particular the forms of dehydration and emptying of the nucleus pulposus known as “black disc disease”. These compositions comprise a hyaluronic acid derivative which forms hydrogels with precise rheological characteristics that make it ideal for filling the nucleus pulposus.

  本发明描述并要求用于治疗椎间盘变性，特别是被称为 "黑椎间盘病 "的髓核脱水和空洞的凝胶状药物组合物。 这些组合物包含一种透明质酸衍生物，它能形成具有精确流变特性的水凝胶，使其成为填充髓核的理想材料。
• PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID FOR USE IN THE TREATMENT OF BLACK DISK DISEASE
  申请人：Fidia Farmaceutici S.p.A.

  公开号：EP2988792A1

  公开（公告）日：2016-03-02
• PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID FOR USE IN THE TREATMENT OF BLACK DISC DISEASE
  申请人：FIDIA FARMACEUTICI S.P.A.

  公开号：US20160067274A1

  公开（公告）日：2016-03-10

  The present invention describes and claims pharmaceutical compositions in gel form for use in the treatment of intervertebral disc degeneration, in particular the forms of dehydration and emptying of the nucleus pulposus known as “black disc disease”. These compositions comprise a hyaluronic acid derivative which forms hydrogels with precise rheological characteristics that make it ideal for filling the nucleus pulposus.
• [EN] PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID FOR USE IN THE TREATMENT OF BLACK DISK DISEASE<br/>[FR] COMPOSITIONS PHARMACEUTIQUES CONTENANT DE L'ACIDE HYALURONIQUE POUR UNE UTILISATION DANS LE TRAITEMENT D'UNE DISCOPATHIE DÉGÉNÉRATIVE
  申请人：FIDIA FARMACEUTICI

  公开号：WO2014174450A1

  公开（公告）日：2014-10-30

  The present invention describes and claims pharmaceutical compositions in gel form for use in the treatment of intervertebral disc degeneration, in particular the forms of dehydration and emptying of the nucleus pulposus known as "black disc disease". These compositions comprise a hyaluronic acid derivative which forms hydrogels with precise rheological characteristics that make it ideal for filling the nucleus pulposus.
• DNA strongly binds to micelles and vesicles containing lipopolyamines or lipointercalants.
  作者：Jean-Paul Behr

  DOI：10.1016/s0040-4039(00)85347-2

  日期：1986.1